Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
30.39
+1.07 (3.65%)
At close: Mar 4, 2026, 4:00 PM EST
30.22
-0.17 (-0.56%)
After-hours: Mar 4, 2026, 5:55 PM EST
Viridian Therapeutics Revenue
In the year 2025, Viridian Therapeutics had annual revenue of $70.85M with 23,359.93% growth. Viridian Therapeutics had revenue of $132.00K in the quarter ending December 31, 2025, with 83.33% growth.
Revenue (ttm)
$70.85M
Revenue Growth
+23,359.93%
P/S Ratio
43.84
Revenue / Employee
$495,448
Employees
143
Market Cap
3.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.85M | 70.55M | 23,359.93% |
| Dec 31, 2024 | 302.00K | -12.00K | -3.82% |
| Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
| Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
| Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
| Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
| Dec 31, 2019 | 4.46M | -3.93M | -46.80% |
| Dec 31, 2018 | 8.39M | 4.38M | 109.49% |
| Dec 31, 2017 | 4.00M | 526.00K | 15.13% |
| Dec 31, 2016 | 3.48M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 909.05M |
| Catalyst Pharmaceuticals | 588.99M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| Arcus Biosciences | 247.00M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
VRDN News
- 6 days ago - Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 7 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 2 months ago - Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
- 2 months ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 4 months ago - Viridian Therapeutics Is Ready For An Eventful 2026 - Seeking Alpha
- 4 months ago - Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
- 4 months ago - Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - Business Wire